Stereotactic body radiation therapy in lymph nodal oligometastatic disease

A prospective study to assess the feasibility of stereotactic body radiation therapy (SBRT) in lymph nodal oligometastatic disease (LN-SBRT) - LN-SBRT

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/02/049773

Enrollment

Registered

2023-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Stereotactic body radiation therapy in lymph nodal oligometastasis from various cancers: The study will be conducted in patients with lymph nodal oligometastasis from various cancers. t

Eligibility

Inclusion criteria

Inclusion criteria: Lymph node oligometastatic disease in the neck, mediastinum, retroperitoneum, or pelvis 2) All primary tumors of colorectal, gastric, esophagus, lung, breast, gynaecological cancers or any other site 3) KPS = 70 4) Age > 18 years

Exclusion criteria

Exclusion criteria: More than 5 metastases 2) KPS = 60 3) Pre-existing collagen vascular disease 4) Age 5) Pregnant and Lactating women 6) Disseminated disease

Design outcomes

Primary

Measure	Time frame
1) To assess Overall survival 2) To assess Progression Free Survival Timepoint: 6 months, 1 year	—

Secondary

Measure	Time frame
1)To evaluate adverse events according CTCAE 2)To evaluate chemotherapy-free survival 3)Quality of life with EORTC QLC C30 Timepoint: At 3 months, 6 months, 12 months	—

Countries

India

Contacts

Public ContactDivya Khosla

Postgraduate Institute of Medical Education and Research

dr_divya_khosla@yahoo.com09876638478

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026